BTIG maintained a Buy rating on Imperva (NYSE: IMPV) with a price target of $55. Analyst Joel P. Fishbein thinks ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE